BKS-db MASH Models

    Study Outline

    图片1.png

    Figure 1. Overview of BKS-db mouse models.


    Data Validation

    1. Body Weight 

    图片2.png

    Figure 2. Weight gain in BKS-db MASH mice after WD induction. Data are presented as Mean±SD, n=5-10.


    2. Blood lipid levels

    图片2-1.png

    Figure 3. After 4 weeks of WD induction, BKS-db MASH mice had higher blood lipid levels than BKS-db normal diet mice. The data are shown as Mean±SD, with n=10-20. **, P<0.01; ***, P<0.001; ****, P<0.0001. by one way ANOVA with Dunnett's post hoc test.


    3. Liver enzymes

    图片3.png

    Figure 4. After 4 weeks of WD induction, BKS-db MASH mice had increased liver enzyme levels compared to BKS-db mice on a normal diet.The data are shown as Mean±SD, with n=10-20. *, P<0.05; **, P<0.01; ****, P<0.0001.  by one way ANOVA with Dunnett's post hoc test.


    4. Liver Phenotype

    图片4.png

    Figure 5. After 4 weeks of WD induction, BKS-db MASH mice developed a severe fatty liver phenotype. The data are shown as Mean±SD, n=5. ****，P<0.0001; by unpaired t test.


    5. Histopathology

    图片5.png

    Figure 6. BKS-db MASH mice showed a more severe inflammatory phenotype, including lipid accumulation and cellular vacuole-like lesions, after 4 weeks of WD induction.


    6. Expression of inflammation, fibrosis-related biomarkers

    图片6.png

    Figure 7. After 4 weeks of WD induction, the expression levels of inflammation, fibrosis-related biomarkers were raised in BKS-db MASH mice. The data are shown as Mean±SD, n=5. *，P<0.05；**，P<0.01；****，P<0.0001; by unpaired t test. 


    Efficacy data

    1. Body Weight

    图片7.png

    Figure 8. Semaglutide significantly reduced the body weight and body weight change rate in BKS-db MASH model. Data are presented as Mean±SD. ***, p<0.001by one way ANOVA with Tukey's post hoc test.


    2. Fasting Blood Glucose

    图片8.png

    Figure 9. Semaglutide significantly reduced fasting glucose in the BKS-db MASH model. Data are presented as Mean±SD, n=5~10. ****, P<0.0001 by one-way ANOVA with Tukey's post hoc test.


    3. Liver function

    图片9.png

    Figure 10. Semaglutide Significantly Improved Liver Function and Dyslipidemia in BKS-db MASH Model. Data are presented as Mean±SD, n=5-10. ****, P<0.0001 by one-way ANOVA with Tukey's post hoc test.


    4. Liver weight

    图片10.png

    Figure 11. Semaglutide significantly reduced liver weight and the liver to body weight ratio in BKS-db MASH model. Data are presented as Mean±SD, n=5~8. ****, P<0.0001 by one-way ANOVA with Tukey's post hoc test.


    5. Histopathology

    图片11.png

    Figure 12. Semaglutide significantly improved the hepatic steatosis, inflammation and ballooning in BKS-db MASH mode. Data were presented as Mean±SD, n=5~8. ****, P<0.0001 by one-way ANOVA with Tukey's post hoc test.


    TALK WITH OUR EXPERTS

    GemPharmatechは、お客様のプライバシーを保護し、尊重することをお約束します。お客様の個人情報は、アカウントの治理およびお客様からご要望いただいた製品やサービスの提供に利用いたします。時折、当社の製品やサービスに関する情報や、お客様に興味があるかもしれない他のコンテンツについてご連絡差し上げたいと考えております。お客様にこの目的をご連絡し、ご同意いただける場合は、以下の要领でお客様にどのようにご連絡させていただけるかをお知らせください。

    ご希望のコンテンツを提供するために、お客様の個人データを生存および処理する须要があります。この目的でお客様の個人データを生存することにご同意いただける場合は、以下のチェックボックスをクリックしてください。

    同意をいつでも撤回する権利があります。購読解除の詳細情報、当社のプライバシーに関する実践、およびお客様のプライバシーを保護し尊重するための取り組みについての詳細については、当社のプライバシーポリシーをご覧ください。